Phase 2 N=30 Prazosin for Alcohol Dependence and Posttraumatic Stress Disorder
Alcohol Abuse · Posttraumatic Stress Disorder
Primary: Percent Drinking Days Per Week — 18.1; 49.3 percentage of drinking days per week
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Bone Metastases · Hormone-resistant Prostate Cancer
Primary: Progression-free Survival — 2.46; 3.65 Months — p=0.06
Phase 2 N=10 Safety of Simvastatin in LAM and TSC
Lymphangioleiomyomatosis · Tuberous Sclerosis Complex
Primary: Safety of Simvastatin in the Treatment of LAM-S and LAM-TS Patients — 0 participants
Phase 2 N=175 Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis
Onychomycosis
Primary: Non-inferiority Will be Determined by Evaluating the Difference Between the Proportion of Patients in the Test and Reference Treatment Groups Who Are Considered a…
Phase 2 N=10 Heart Rate Variability Biofeedback for Smoking Cessation
Tobacco Smoking
Primary: Intervention Feasibility: Participant Attendance — 6.30; 8.71 Sessions
Phase 2 N=12 Alimta Plus Gemcitabine for Advanced Sarcoma
Sarcoma, Soft Tissue
Primary: Tumor Best Response Rate — 0 Participants
Phase 2 N=35 A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy
Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns
Primary: Survival at One Year — 16; 17 Participants
Phase 2 N=42 Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Thyroid Cancer
Primary: Number of Participants With Response Per Responsive Evaluation Criteria in Solid Tumors Criteria (RECIST v1.0) — 17; 9; 11 Participants
Phase 2 N=80 Clonidine Added Lidocaine in Intraocular Pressure and Hemodynamics Ocular in Sub-Tenon's and Peribulbar Anesthesia
Anesthesia
Primary: Intraocular Pressure (IOP) — 18; 16; 19; 16 mmHg
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Phase 2 N=22 Clinical Evaluation of Lyral® Dose Response Study
Contact Dermatitis
Primary: Number of Participants With Positive Patch Test Responses — 14; 12; 11; 0 participants
Phase 2 N=22 3D Augmented Reality Mirror Visual Feedback Applied to the Treatment of Unilateral Upper Extremity Neuropathic Pain.
Neuralgia
Primary: Pain on the Visual Analog Scale (VAS) — 6.4; 4.0 units on a scale
Phase 2 N=3 Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency
Gastrointestinal Inflammation Associated With CVID · CVID Enteropathy
Primary: Number of Participants With Increase in Infection or Serious Adverse Events (SAEs) Related to Single Dose Administration of Ustekinumab — 0 participants
Phase 2 N=56 Clinical Evaluation of Metal Panel Allergens: Mercury, Aluminum and Palladium Dose Response Study
Contact Dermatitis
Primary: Number of Participants Who Exhibit Positive Responses to Each Allergen Concentration — 4; 0; 0; 2 Participants
Phase 2 N=79 Follow up 18F-AV-1451 Scan in Confirmatory Cohort Subjects From Study 18F-AV-1451-A05
Alzheimer's Disease
Primary: Change in Tau Deposition Over Time by Diagnostic Group and Amyloid Status — 0.0205; -0.0912; 0.0352; -0.0124 standardized uptake value ratio (SUVr) — p=0.0166